Oral Bioavailability of a New Formulation of Pterostilbene Cocrystal in Comparison With Its Free Form (BIOPTERO2)

Biological Availability Clinical Trial

— BIOPTERO2  

Official title:

Evaluation of the Oral Bioavailability of a New Formulation of Pterostilbene Co-crystal in Comparison With Its Free Form in Healthy Volunteers: Crossover, Randomized and Simple Blind Study (BIOPTERO2)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06289140
• Other study ID #: BIOPTERO2
• Status: Not yet recruiting
• Phase: N/A
• Start date: March 2024
• Est. completion date: April 2024

Study information

• Verified date: February 2024
• Source: Fundació Eurecat
• Contact: Antoni Caimari, PhD
• Phone: 0034 977 300 431
• Email: antoni.caimari[@]eurecat.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this interventional study is to to evaluate the oral bioavailability of the crystallized form of pterostilbene (ccPT) compared to its commercial free base form (pterostilbene (PT) in healthy volunteers. The main question it aims to answer are: • Do the crystallized forms of pterostilbene (ccPT) using two different encapsulation methods exhibit greater bioavailability than its commercial free base form (PT)? Participants will attend to four visits: a preselection visit (V0), a visit for the first postprandial study (V1), a visit for the second postprandial study (V2) after one-week washing period and a visit for the third postprandial study (V3) after another one week washing period. Researchers will analyze the three postprandial assays to determine which type of ccPT encapsulation provides the highest bioavailability compared to the commercial free base form (PT).

Description:

The oxidative stress (OS) is a condition where pro-oxidative processes overwhelm cellular antioxidant defenses due to disruption in redox signaling. This results in the body's inability to eliminate reactive oxygen species (ROS) or repair damages, potentially leading to severe impacts on cells, tissues, and organs. Pterostilbene (PT) is a stilbenoid found in various natural sources, emerging as an antioxidant with potential preventive and therapeutic properties in numerous diseases. Despite its promising properties, PT's low water solubility and bioavailability pose challenges. Nutraceutical co-crystallization is a recent strategy to enhance solubility and oral bioavailability. It has been identified that a new pterostilbene:picolinic acid (1:1) co-crystal, significantly increasing solubility and oral bioavailability compared to commercial free base PT. The study aims to evaluate oral bioavailability (AUC0-24h) of PT (free and total) from ccPT compared to commercial PT, using two different encapsulation methods. Secondary objectives include determining pharmacokinetic parameters such as AUCinf, relative oral bioavailability (Frel), Cmax, Tmax, and T1/2 for both free and total PT. This randomized, crossover, single-blind clinical trial aims to provide insights into the effectiveness of the new ccPT formulation in enhancing PT's oral bioavailability compared to the commercial PT formulation.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 6
• Est. completion date: April 2024
• Est. primary completion date: April 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Men and women between 18 and 65 years of age.
• Sign the informed consent form.
• Know how to read, write and speak Spanish

Exclusion Criteria:

• Take supplements or multivitamin supplements or phytotherapeutic products (especially infusions) that interfere with the treatment under study up to 30 days before the start of the study.
• Be lacto-vegetarian, lacto-ovo-vegetarian, or vegan.
• Present intolerances and/or food allergies related to pterostilbene or the excipients.
• Be a smoker.
• Having received antibiotic treatment up to 30 days before the start of the study.
• Present values of body mass index = 18kg/m^2 or = 35 kg/m^2.
• Present some chronic disease with clinical manifestations: coronary heart disease, cardiovascular disease, diabetes, celiac disease, Crohn's disease, chronic kidney disease, cancer, autoimmune diseases (such as fibromyalgia), respiratory and/or gastrointestinal diseases that may compromise the absorption of the compound.
• Clinical history of anemia.
• Being pregnant or intending to became pregnant.
• Be in breastfeeding period.
• Being unable to follow the study guidelines.
• Participate in or have participated in a clinical trial or nutritional intervention study in the last 30 days before inclusion in the study.

Related Conditions & MeSH terms

• Biological Availability

Intervention

Dietary Supplement:
• Pterostilbene cocrystal (ccPT) - Gelatin capsule
Participants will intake one gelatin capsule with 75 mg of Pterostilbene cocrystal (ccPT).
• Pterostilbene free form (PT)
Participants will intake one capsule with 50 mg of Pterostilbene free form (PT)
• Pterostilbene cocrystal (ccPT) - Gastro-resistant capsule
Participants will intake one gastro-resistant capsule with 75 mg of Pterostilbene cocrystal (ccPT).

Locations

Country	Name	City	State
Spain	Fundació Eurecat	Reus

Sponsors (2)

Lead Sponsor	Collaborator
Fundació Eurecat	Circe, S.L.

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Bioavailability of Pterostilbene calculated by area under the curve (AUC 0-24) of plasma pterostilbene levels, both free and total.	Fasting pterostilbene levels in plasma will be determined by liquid chromatography coupled to mass spectrophotometry before consume the capsule with pterostilbene until 24 hours postprandially at 8 points after consuming the capsule (0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 24 hours).; Total PT will be quantified indirectly after hydrolysis of the conjugated glucuronide and sulfate metabolites to free PT in the presence of ß-glucuronidase and arylsulfatase in the plasma samples.	At week 1, week 2 and week 3
Secondary	Area under the curve (AUC 0-inf) of plasma pterostilbene levels, both free and total.	Fasting pterostilbene levels in plasma will be determined by liquid chromatography coupled to mass spectrophotometry before consume the capsule with pterostilbene until 24 hours postprandially at 8 points after consuming the capsule (0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 24 hours).; Total PT will be quantified indirectly after hydrolysis of the conjugated glucuronide and sulfate metabolites to free PT in the presence of ß-glucuronidase and arylsulfatase in the plasma samples.	At week 1, week 2 and week 3
Secondary	Relative bioavailability of plasma pterostilbene levels (Frel).	Relative bioavailability of plasma pterostilbene levels, both free and total	At week 1, week 2 and week 3
Secondary	Maximum plasma concentration (Cmax)	Maximum plasma concentration of pterostilbene, total and free.	At week 1, week 2 and week 3
Secondary	Time for maximum plasma concentration (Tmax)	Time period for the maximum plasma concentration of pterostilbene, both total and free.	At week 1, week 2 and week 3
Secondary	Half-life (T1/2).	Time taken for half the initial dose of pterostilbene, both total and free, administered to be eliminated from the body.	At week 1, week 2 and week 3

External Links

•   Technological Centre of Nutrition and Health. Eurecat_Reus.